

We thank the reviewer for the helpful comments. Following those suggestion, we have revised the manuscript as outlined below. We hope that the revisions will enable you to accept this version of the manuscript.

Response to Reviewer #1 Comments

Point 1: What is more, in the previous four months two new meta-analyses (Nisly et al. J Thromb Thrombolysis Mar 2021 and Meninchelli et al Eur J Clin Invest Mar 2021 |) have added new information in the field, underlining the safety and efficacy of DOACs in cirrhosis. Finally, an excellent relevant recent study has been published in January 2021 in Hepatology. In this retrospective longitudinal study by Serper et al, the researchers have once more highlighted the safety of DOACs in patients with cirrhosis, using national data of US veterans with cirrhosis. Moreover, they observed a possible effect of DOACs in ameliorating all-cause mortality in patients with cirrhosis. Additionally, they also found that hepatic decompensation was lower with both warfarin and DOACs in analyses limited to marginal structural models. According to the reviewer, the authors should consider adding all three aforementioned articles in their paper.

Response 1: thanks to the Reviewer for giving us the opportunity to better address this point. We added an explanation and we cited all documents suggested in the text (section *"Safety of DOACs in cirrhosis: current evidence"*).